

# Handbook of Experimental Pharmacology

Continuation of Handbuch der experimentellen Pharmakologie

## Vol. 70/II

### *Editorial Board*

G. V. R. Born, London · A. Farah, Rensselaer, New York  
H. Herken, Berlin · A. D. Welch, Bethesda, Maryland

### *Advisory Board*

S. Ebashi · E. G. Erdös · V. Erspamer · U. S. von Euler · W. S. Feldberg  
G. B. Koelle · M. Rocha e Silva · J. R. Vane · P. G. Waser

# Pharmacology of Intestinal Permeation II

## Contributors

J. G. Banwell · P. Bass · T. Z. Csáky · A. M. Dawson · J. M. Dietschy  
K. Ewe · G. W. Gullikson · T. R. Hendrix · S. Hughes  
N. N. Jezuitova · F. Lauterbach · M. Lucas · J. S. McKay  
K. J. Moriarty · G. Nell · W. Rummel · L. F. Smirnova · M. Staritz  
A. B. R. Thomson · L. A. Turnberg · A. M. Ugolev · V. Varró  
R. Wanitschke · D. Winne

## Editor

T. Z. Csáky



Springer-Verlag

Berlin Heidelberg New York Tokyo 1984

TIHAMÉR Z. CSÁKY, M.D.  
Professor of Pharmacology  
Department of Pharmacology  
University of Missouri-Columbia  
School of Medicine  
Columbia, MO 65212  
USA

With 149 Figures

Library of Congress Cataloging in Publication Data. Main entry under title: Pharmacology of intestinal permeation. (Handbook of experimental pharmacology; vol. 70/I-II) Includes bibliographical references and index. 1. Intestinal absorption. 2. Gastrointestinal agents – Physiological effect. I. Armstrong, W. McDermott (William McDermott) II. Csáky, T. Z. III. Series: Handbook of experimental pharmacology; v. 70/I-II. [DNLM: 1. Intestinal Absorption. 2. Intestines – metabolism. 3. Cell Membrane Permeability – drug effects. 4. Drugs – metabolism. W1 HA51L v. 70 pt. 1-2/WI 402 P536] QP905.H3 vol. 70/I-II 615'.1 s 84-5558 [QP156] [612'.33]

ISBN-13: 978-3-642-69510-0

e-ISBN-13: 978-3-642-69508-7

DOI: 10.1007/978-3-642-69508-7

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law, where copies are made for other than private use, a fee is payable to “Verwertungsgesellschaft Wort”, Munich.

© by Springer-Verlag Berlin Heidelberg 1984

Softcover reprint of the hardcover 1st edition 1984

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

2122/3130-543210

# List of Contributors

- J. G. BANWELL, Department of Medicine, Division of Gastroenterology, Case Western School of Medicine, Cleveland, OH 44106, USA
- P. BASS, School of Pharmacy, University of Wisconsin, 425 N. Charter Street, Madison, WI 53706, USA
- T. Z. CSÁKY, Professor of Pharmacology, Department of Pharmacology, University of Missouri-Columbia, School of Medicine, Columbia, MO 65212, USA
- A. M. DAWSON, Department of Gastroenterology, St. Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, Great Britain
- J. M. DIETSCHY, Department of Internal Medicine, University of Texas, Health Science Center, Southwestern Medical School, Dallas, TX 75235, USA
- K. EWE, I. Medizinische Klinik und Poliklinik, Johannes Gutenberg Universität, Postfach 3960, Langenbeckstraße 1, 6500 Mainz, FRG
- G. W. GULLIKSON, Research Investigator, Department of Biological Research, Searle Research and Development, Division of G. D. Searle & Co., Box 5110, Chicago, IL 60680, USA
- T. R. HENDRIX, Department of Medicine, Chief Gastroenterology Division, The John Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21205, USA
- S. HUGHES, Department of Medicine, Hope Hospital, (University of Manchester School of Medicine), Eccles Old Road, Salford M6 8HD, Great Britain
- N. N. JEZUITOVA, J.-O. Pavlov Institute of Physiology, The Academy of Sciences of the USSR, Nab. Makarova, 6, Leningrad, 199164, USSR
- F. LAUTERBACH, Institut für Pharmakologie und Toxikologie, Ruhr-Universität Bochum, Postfach 102148, 4630 Bochum 1, FRG
- M. LUCAS, Institute of Physiology, The University of Glasgow, Glasgow, W.2 Great Britain
- J. S. MCKAY, Department of Medicine, Hope Hospital, (University of Manchester School of Medicine), Eccles Old Road, Salford M6 8HD, Great Britain
- K. J. MORIARTY, Department of Gastroenterology, St. Bartholomew's Hospital, West Smithfield, London, EC1A 7BE. Present address: Department of Medicine, Hope Hospital (University of Manchester School of Medicine), Eccles Old Road, Salford M6 8HD, Great Britain

- G. NELL, Institut für Pharmakologie und Toxikologie der Universität des Saarlandes, 6650 Homburg (Saar), FRG
- W. RUMMEL, Institut für Pharmakologie und Toxikologie der Universität des Saarlandes, 6650 Homburg (Saar), FRG
- L. F. SMIRNOVA, I. P. Pavlov Institute of Physiology, The Academy of Sciences of the USSR, Nab. Makarova, 6, Leningrad, 199164, USSR
- M. STARITZ, I. Medizinische Klinik und Poliklinik, Langenbeckstraße 1, 6500 Mainz, FRG
- A. B. R. THOMSON, University of Alberta, Edmonston, Alberta, CDN
- L. A. TURNBERG, Department of Medicine, Hope Hospital, (University of Manchester School of Medicine), Eccles Old Road, Salford M6 8HD, Great Britain
- A. M. UGOLEV, I. P. Pavlov Institute of Physiology, The Academy of Sciences of the USSR, Nab. Makarova, 6, Leningrad, 199164, USSR
- V. VARRÓ, First Department of Medicine, University Medical School, P.B. 469, 6701 Szeged, Hungary
- R. WANITSCHKE, I. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität, Postfach 3960, Langenbeckstraße 1, 6500 Mainz, FRG
- D. WINNE, Abt. für Molekularpharmakologie, Pharmakologisches Institut der Universität Tübingen, Wilhelmstraße 56, 7400 Tübingen 1, FRG

# Preface

The intestine, particularly the small bowel, represents a large surface (in the adult human approximately 200 m<sup>2</sup>) through which the body is exposed to its environment. A vigorous substrate exchange takes place across this large surface: nutrients and xenobiotics are absorbed from the lumen into the bloodstream or the lymph, and simultaneously, the same types of substrate pass back into the lumen. The luminal surface of the intestine is lined with a "leaky" epithelium, thus the passage of the substrates, in either direction, proceeds via both transcellular and intercellular routes. Simple and carrier-mediated diffusion, active transport, pinocytosis, phagocytosis and persorption are all involved in this passage across the intestinal wall.

The term "intestinal permeation" refers to the process of passage of various substances across the gut wall, either from the lumen into the blood or lymph, or in the opposite direction. "Permeability" is the condition of the gut which governs the rate of this complex two-way passage.

The pharmacologist's interest in the problem of intestinal permeation is twofold: on the one hand, this process determines the bioavailability of drugs and contributes significantly to the pharmacokinetics and toxicokinetics of xenobiotics; on the other hand, the pharmacodynamic effects of many drugs are manifested in a significant alteration of the physiological process of intestinal permeation.

The material in these volumes was collected in order to present some of the fundamental aspects of the permeability and the permeation of the intestine. An attempt has been made to include morphological, physicochemical, physiologic, biophysical, biochemical, pharmacologic and toxicologic aspects. Clearly, intestinal permeation cannot be properly studied from the perspective of one or a few disciplines; the subject cuts across a wide spectrum of disciplines. Consequently, it is hoped that the information provided in these volumes will be useful to scientists working in a variety of specialties.

I would like to express my thanks to those colleagues who accepted my invitation and contributed to this publication. It is somewhat unfortunate that the collection of the material required a considerable amount of time, but in a publication of this size, with a large number of contributors, some delay is inevitable. One prospective contributor was prevented from completing his task by a fatal heart attack, while others had to be excused because they failed to find enough time for the work. Fortunately, outstanding replacements were secured, but not without some holdup. Our knowledge of fundamental principles seldom changes in a revolutionary fashion, thus, despite the spread in time, it is hoped

that these volumes will provide the reader with the information necessary to form a correct contemporary image of the complex process of intestinal permeation and the conditions of permeability.

Finally, I would like to thank my wife for lending me a helping hand, amidst her own professional duties, in various aspects of the editorial work.

T. Z. CSÁKY

# Contents

## CHAPTER 18

### **Intestinal Absorption of Xenobiotics.** T. Z. CSÁKY. With 5 Figures

A. Introduction . . . . .	1
B. Drug Absorption and Pharmacologic Response . . . . .	1
C. The Side of Drug Absorption . . . . .	2
D. The Intestinal Barrier and its Permeability . . . . .	3
I. The Unstirred Water Layer . . . . .	4
II. The Transcellular Route . . . . .	5
III. The Intercellular Route . . . . .	10
IV. Absorption via the Lymph . . . . .	11
E. Factors Which Influence the Intestinal Absorption of Xenobiotics . . . . .	12
I. Factors Inherent to the Drug Molecule . . . . .	12
II. Factors Inherent of Pharmaceutical Formulation . . . . .	13
III. Factors Inherent to Intestinal Permeability . . . . .	13
IV. Factors Inherent to the Patient . . . . .	13
References . . . . .	23

## CHAPTER 19

### **Role of Digestive Enzymes in the Permeability of the Enterocyte**

A. M. UGOLEV, N. N. IEZUITOVA, and L. F. SMIRNOVA. With 26 Figures

A. Introduction . . . . .	31
B. Relationship Between the Hydrolytic and Transport Systems of the Enterocytes . . . . .	32
I. The Basic Types of Digestion and Their Relation to Absorption . . . . .	32
II. Membrane Digestion and Digestive-Absorptive Functions of the Enterocyte Membrane . . . . .	34
III. Classification of Digestive Processes . . . . .	37
IV. The Enzyme Apparatus of Membrane Digestion . . . . .	38
V. Membrane Digestion in Normal Function of the Gastrointestinal Tract . . . . .	47
C. Enzyme Apparatus of the Apical Membrane of the Enterocytes . . . . .	49
I. Fine Location of Membrane Hydrolases . . . . .	49
II. The Amphipathic Structure of Membrane Enzymes . . . . .	53
III. Functions of the Hydrophobic Part of Intestinal Enzymes . . . . .	58
IV. Characterization of Hydrolases . . . . .	61



D. Characterization of the Transport of Free Monomers and Hydrolysis-Released Monomers . . . . .	66
I. Comparison of the Rates of Absorption of Oligomers and Monomers . . . . .	67
II. Factors Affecting the Relationship Between Oligomer and Monomer Transport . . . . .	78
III. Kinetic Characteristics of Oligomer and Monomer Transport . . . . .	80
IV. Competitive Interactions Between Free and Hydrolysis-Released Monomers . . . . .	81
V. Role of Na <sup>+</sup> in the Transport of Hydrolysis-Released and Free Monomers . . . . .	84
E. The Enzyme Transport Complexes of the Apical Membrane of the Enterocytes . . . . .	86
I. Cooperative Interactions Between Enzymatic and Transport Parts . . . . .	87
II. Allosteric Interactions Between Enzyme and Transport Parts . . . . .	89
III. Possible Molecular Models . . . . .	93
IV. The Permeome . . . . .	93
F. Conclusion . . . . .	95
I. Adaptability and Regulation of the Enzyme Transport Complexes . . . . .	96
II. The Enzyme Transport Complexes of the Membrane in Pathology . . . . .	97
III. Concluding Remarks . . . . .	98
References . . . . .	98

## CHAPTER 20

**The Surface pH of the Intestinal Mucosa and its Significance in the Permeability of Organic Anions.** M. LUCAS. With 14 Figures

A. Introduction . . . . .	119
B. Intestinal pH Measurements . . . . .	121
C. Acidification Studies . . . . .	122
I. The Effect of Mucosal Glucose Concentration . . . . .	122
II. The Involvement of Carbonic Anhydrase . . . . .	122
III. Sodium Ion Exchange Mechanisms . . . . .	123
IV. Hydrogen-Potassium Exchange . . . . .	124
V. Acidification and Electrical Events . . . . .	124
VI. The Mechanism of Hydrogen Ion Secretion . . . . .	125
VII. Hormonal Effects . . . . .	126
VIII. Infectious Agents . . . . .	126
D. The Intestinal Acid Microclimate . . . . .	127
I. Evidence for the Microclimate Hypothesis . . . . .	127
II. Clinical Studies . . . . .	134
III. Related Phenomena . . . . .	135
IV. The Role of Mucus . . . . .	137
E. Alternative Concepts . . . . .	137
I. The Unstirred Layer Hypothesis . . . . .	137
II. Permeation of Ionised Forms . . . . .	141
III. Extraction Theory . . . . .	142

F. Absorption and the Microclimate Hypothesis: Three Paradigms . . .	143
I. Folic Acid Absorption . . . . .	143
II. Fatty Acid Absorption . . . . .	145
III. Propranolol Absorption . . . . .	148
G. Modelling the System . . . . .	149
H. Conclusion . . . . .	154
References . . . . .	155

CHAPTER 21

**The Role of the Unstirred Water Layer in Intestinal Permeation**

A. B. R. THOMSON and J. M. DIETSCHY. With 55 Figures

A. Unstirred Water Layers: Historical and Conceptual Background . . .	165
B. Water Compartments In and Around the Intestinal Mucosal Cell . .	168
C. Comparison of Dimensions of the Unstirred Water Layer with Morphological Parameters . . . . .	170
D. The Glycocalyx and Mucus as Diffusion Barriers . . . . .	173
E. Intestinal Membrane Structure . . . . .	173
F. Movement of Solutes Across Biologic Membranes: General Principles	175
G. Effects of Aqueous Diffusion Barriers on Solute Movement . . . . .	178
H. A Consideration of Surface Areas . . . . .	180
J. Consequences of Failure to Correct for the Unstirred Water Layer and Passive Permeation . . . . .	185
K. Diffusion Barriers of Greater Complexity . . . . .	190
L. Possible Functional Heterogeneity of the Villus . . . . .	190
M. Effect of Carrier Molecules, Solubility of Probe, and Metabolism in the Cytosolic Compartment . . . . .	193
N. Effect of Membrane Polarity on Penetration of Passively Transported Molecules . . . . .	197
O. Anomalous Behavior of Diffusion of Certain Solutes Across the Intestine . . . . .	202
P. Methods Available for the Measurement of the Dimensions of the Unstirred Water Layer . . . . .	204
I. Effective Thickness of the Unstirred Water Layer . . . . .	204
II. Effective Surface Area of the Unstirred Water Layer . . . . .	213
Q. Examples of the Effect of Unstirred Water Layers on Intestinal Transport . . . . .	216
I. Estimates of the Temperature Coefficient . . . . .	216
II. Estimates of Kinetic Constants of Carrier-Mediated Transport . .	218
III. Permeation of Weak Electrolytes: Acid Microclimate . . . . .	250
IV. Effect of Volume Flow, "Sweeping Away" Effects, and Unstirred Layers on the Estimation of Effective Osmotic Pressure Across a Membrane . . . . .	254
V. Membrane "Pores" . . . . .	255
VI. Potential Role of the Intestinal Unstirred Water Layer in Disease	258
References . . . . .	259

## CHAPTER 22

**Intestinal Permeation of Organic Bases and Quaternary Ammonium Compounds.** F. LAUTERBACH. With 12 Figures

A. Introduction . . . . .	271
B. Absorption of Organic Bases and Quaternary Ammonium Compounds	272
I. Dependence on Polarity . . . . .	272
II. Dependence on Concentration . . . . .	275
III. Dependence on Time . . . . .	276
C. Intestinal Secretion of Organic Cations . . . . .	277
I. Secretion by the Isolated Mucosa of Guinea-Pig Small Intestine . . . . .	277
II. Substrate Specificity . . . . .	279
III. Localization of the Secretory System in the Enterocyte . . . . .	281
IV. In Vivo Secretion . . . . .	286
D. A Concept for the Intestinal Permeation of Organic Cations . . . . .	286
E. Comparative Aspects of Organic Cation Secretion . . . . .	291
I. Intestinal Secretion of Other Xenobiotics . . . . .	291
II. Secretion of Organic Cations by Other Organs . . . . .	291
F. Conclusions . . . . .	292
References . . . . .	293

## CHAPTER 23

**Role of Blood Flow in Intestinal Permeation.** D. WINNE. With 8 Figures

A. Introduction . . . . .	301
B. Methods . . . . .	302
C. Theoretical Considerations . . . . .	305
D. Experimental Data . . . . .	307
I. Dependence of Intestinal Absorption on Total Intestinal Blood Flow Rate . . . . .	307
II. Dependence of Intestinal Absorption on Intramural Blood Flow Pattern . . . . .	332
III. Role of Villous Countercurrent Exchange in Intestinal Absorption . . . . .	335
E. Concluding Remarks . . . . .	337
References . . . . .	338

## CHAPTER 24

**Hormonal Effects on Intestinal Permeability.** V. VARRÓ

A. Introduction . . . . .	349
B. Gastrin . . . . .	350
I. In Vitro Studies . . . . .	350
II. In Vivo Studies . . . . .	351
C. Cholecystokinin . . . . .	352
D. Vasoactive Intestinal Polypeptide . . . . .	353
I. In Vitro Studies . . . . .	353

II. In Vivo Studies . . . . .	354
III. VIP-Secreting Tumors . . . . .	354
E. Secretin . . . . .	356
F. Insulin . . . . .	357
I. Influence of Exogenous Insulin on Intestinal Permeability . . . . .	357
G. Glucagon . . . . .	361
I. Effect on Intestinal Water and Electrolyte Movements . . . . .	361
II. Endogenous Hyperglucagonemia . . . . .	363
III. Effect on Sugar and Amino Acid Absorption In Vivo . . . . .	364
IV. Effect on Sugar and Amino Acid Transfer In Vitro . . . . .	368
V. Effect on Portal Glucose Transport . . . . .	368
VI. Changes of Mucosal cAMP and cGMP Levels After Glucagon Treatment in the Rat Small Intestine . . . . .	370
VII. Intestinal Mucosal Adaptation to Glucagon . . . . .	371
H. Other Gastrointestinal Polypeptides . . . . .	371
I. Gastric Inhibitory Polypeptide . . . . .	371
II. Pancreatic Polypeptide . . . . .	371
III. Somatostatin . . . . .	372
IV. Sorbin . . . . .	372
J. General Remarks on the Effects of Gastrointestinal Hormones on Intestinal Permeation . . . . .	373
References . . . . .	374

CHAPTER 25

**The Influence of Opiates on Intestinal Transport**

J. S. MCKAY, S. HUGHES, and L. A. TURNBERG. With 4 Figures

A. Introduction . . . . .	381
B. In Vivo Studies . . . . .	381
C. In Vitro Studies . . . . .	382
I. Opiate Receptors . . . . .	382
II. Possible Neural Mediation . . . . .	383
D. Ion Flux Responses . . . . .	384
E. Antisecretory Activity . . . . .	385
F. Summary . . . . .	388
References . . . . .	388

CHAPTER 26

**Effect of Cholera Enterotoxin on Intestinal Permeability**

T. R. HENDRIX

A. Introduction . . . . .	391
B. Cholera Enterotoxin-Intestinal Interaction . . . . .	391
I. The Enterotoxin . . . . .	392
II. Enterotoxin-Enterocyte Interaction . . . . .	392
III. Enterotoxin Activation of Adenylate Cyclase . . . . .	392
IV. Cyclic AMP and Intestinal Secretion . . . . .	392

C. Role of Increased Filtration in the Production of Cholera-Induced Intestinal Secretion . . . . .	393
I. Increased Intestinal Permeability . . . . .	393
II. Increased Driving Force . . . . .	396
D. Conclusion . . . . .	398
References . . . . .	398

## CHAPTER 27

**Aspects of Bacterial Enterotoxins Other than Cholera on Intestinal Permeability.** J. G. BANWELL

A. Introduction . . . . .	401
B. <i>Escherichia coli</i> . . . . .	402
I. Heat-Labile Toxin . . . . .	402
II. Heat-Stable Toxin . . . . .	404
III. Relationship of Surface Adhesion (Colonization Factors) to Fluid Secretion . . . . .	405
IV. Surface Mucosal Invasion (Enteroadherence) . . . . .	406
C. <i>Shigella</i> . . . . .	406
D. Prostaglandin Released from Inflamed Tissue and Fluid and Electrolyte Secretion . . . . .	408
E. <i>Salmonella</i> . . . . .	408
I. <i>Salmonella</i> Enteritis . . . . .	408
II. Role of Increased Capillary Hydrostatic Pressure and Transmucosal Permeability . . . . .	409
III. Role for a <i>Salmonella</i> Enterotoxin . . . . .	409
F. <i>Pseudomonas aeruginosa</i> . . . . .	409
G. <i>Campylobacter fetus</i> . . . . .	410
H. <i>Yersinia enterocolitica</i> . . . . .	410
J. Noncoliform Enterobacteriaceae . . . . .	411
I. <i>Klebsiella pneumoniae</i> Toxin . . . . .	411
II. <i>Enterobacter cloacae</i> Toxin . . . . .	411
III. <i>Aeromonas hydrophila</i> Toxin . . . . .	411
K. Food Poisoning Organisms . . . . .	411
I. <i>Bacillus cereus</i> Toxin . . . . .	411
II. Clostridial Toxin . . . . .	412
L. <i>Staphylococcus</i> . . . . .	412
M. Additional Mechanisms for Toxin-Mediated Permeation Defects . . . . .	413
I. Evidence for a Role for Calcium . . . . .	413
II. Filtration Secretion . . . . .	413
References . . . . .	414

## CHAPTER 28

**Mechanisms of Action of Laxative Drugs**

G. W. GULLIKSON and P. BASS. With 5 Figures

A. Introduction . . . . .	419
---------------------------	-----

B. Intestinal Tract Smooth Muscle Response to Laxatives . . . . .	420
C. Effects of Laxatives on Fluid and Electrolyte Movement . . . . .	425
I. Cellular and Mucosal Damage . . . . .	429
II. Enhanced Mucosal Permeability . . . . .	431
III. Role of cAMP in the Actions of Laxatives . . . . .	433
IV. Effects of Laxatives on $\text{Na}^+$ , $\text{K}^+$ -ATPase and Energy Metabolism . . . . .	435
V. Hormones as Mediators of Laxative Action . . . . .	435
D. Bulk and Dietary Fibers . . . . .	438
I. Water-Retaining Properties . . . . .	439
II. Role of Bacteria in the Action of Bulk Laxatives . . . . .	440
III. Altered Transit Time . . . . .	442
IV. Fiber Interaction . . . . .	443
V. Carbohydrate Laxative Drugs . . . . .	445
E. Summary . . . . .	447
References . . . . .	447

CHAPTER 29

**Action Mechanisms of Secretagogue Drugs**

G. NELL and W. RUMMEL. With 5 Figures

A. Introduction . . . . .	461
B. Theoretical Considerations . . . . .	462
I. Inhibition of Active Absorption . . . . .	463
II. Active Secretion . . . . .	464
III. Filtration . . . . .	464
C. Triarylmethane and Anthraquinone Derivatives . . . . .	465
I. Effect on Intestinal Fluid and Electrolyte Transfer . . . . .	465
II. Chemistry, Structure–Activity Relationship, and Pharmacokinetics . . . . .	465
III. Proposed Action Mechanisms . . . . .	467
IV. Conclusion . . . . .	473
D. Surfactants . . . . .	475
I. Effect on Intestinal Fluid and Electrolyte Transfer . . . . .	475
II. Structure–Activity Relationship . . . . .	480
III. Proposed Action Mechanisms . . . . .	482
IV. Conclusions . . . . .	491
E. General Summary and Concluding Remarks . . . . .	495
References . . . . .	496

CHAPTER 30

**Use and Abuse of Cathartics**

K. J. MORIARTY and A. M. DAWSON

A. Introduction . . . . .	509
B. Classification . . . . .	510
I. Bulking Agents . . . . .	510
II. Contact Cathartics . . . . .	511

III. Stool Softeners . . . . .	513
IV. Osmotic Laxatives . . . . .	514
V. Per Rectum Evacuants . . . . .	514
C. Indications for Use . . . . .	515
I. Constipation . . . . .	515
II. The Irritable Bowel Syndrome . . . . .	516
D. Laxative Abuse . . . . .	516
I. Habitual Abuse . . . . .	516
II. Surreptitious Abuse . . . . .	519
E. Summary . . . . .	525
References . . . . .	526

## CHAPTER 31

**Intestinal Permeability Studies in Humans**

K. EWE, R. WANITSCHKE, and M. STARITZ. With 15 Figures

A. Introduction . . . . .	535
B. Methods for Studying Intestinal Permeability in Humans . . . . .	535
I. Intestinal Perfusion . . . . .	535
II. Intestinal Permeability Studied by Test Molecules . . . . .	540
III. Electrical Transmucosal Potential Difference . . . . .	545
C. Permeability Characteristics of the Human Gut . . . . .	547
I. Studies Employing Intestinal Intubation and Perfusion . . . . .	547
II. Selectivity of Cation Permeability . . . . .	550
III. Transcellular Intestinal Permeability . . . . .	550
IV. Unstirred Water Layer and Intestinal Permeability . . . . .	554
V. Intestinal Permeability to Peptide Macromolecules . . . . .	555
VI. Persorption of Particles . . . . .	557
D. Influence of Drugs on Intestinal Permeability . . . . .	559
I. Influence on Electrolyte and Water Transfer . . . . .	559
II. Change in Intestinal Permeability by Cytostatic Treatment . . . . .	560
E. Intestinal Permeability in Disease . . . . .	561
I. Coeliac Disease . . . . .	561
II. Inflammatory Bowel Disease . . . . .	563
References . . . . .	565
<b>Subject Index . . . . .</b>	<b>573</b>

# Contents of Companion Volume 70, Part I

## CHAPTER 1

### **Morphology of the Intestinal Mucosa**

K. E. CARR and P. G. TONER. With 35 Figures

## CHAPTER 2

### **Intestinal Permeation and Permeability: an Overview**

T. Z. CSÁKY. With 4 Figures

## CHAPTER 3

### **Permeability and Related Phenomena: Basic Concepts**

V. CAPRARO. With 15 Figures

## CHAPTER 4

### **Methods for Investigation of Intestinal Permeability**

T. Z. CSÁKY. With 14 Figures

## CHAPTER 5

### **Vascular Perfusion of Rat Small Intestine for Permeation and Metabolism Studies**

H. G. WINDMUELLER and A. E. SPAETH. With 20 Figures

## CHAPTER 6

### **The Use of Isolated Membrane Vesicles in the Study of Intestinal Permeation**

H. MURER and B. HILDMANN. With 13 Figures

## CHAPTER 7

### **The Transport Carrier Principle**

W. D. STEIN. With 21 Figures

## CHAPTER 8

### **Energetics of Intestinal Absorption**

D. S. PARSONS. With 5 Figures

## CHAPTER 9

### **Polarity of Intestinal Epithelial Cells: Permeability of the Brush Border and Basolateral Membranes**

G. ESPOSITO



## CHAPTER 10

**Electrical Phenomena and Ion Transport in the Small Intestine**

W. MCD. ARMSTRONG and J. F. GARCIA-DIAZ. With 6 Figures

## CHAPTER 11

**Intestinal Permeation of Water**

K. TURNHEIM. With 4 Figures

## CHAPTER 12

**Intestinal Permeability to Calcium and Phosphate**

L. R. FORTE. With 1 Figure

## CHAPTER 13

**Protein-Mediated Epithelial Iron Transfer**

H. HUEBERS and W. RUMMEL. With 6 Figures

## CHAPTER 14

**Intestinal Absorption of Heavy Metals**

E. C. FOULKES. With 6 Figures

## CHAPTER 15

**Intestinal Permeability of Water-Soluble Nonelectrolytes:****Sugars, Amino Acids, Peptides.** G. ESPOSITO. With 5 Figures

## CHAPTER 16

**Pharmacologic Aspects of Intestinal Permeability to Lipids****(Except Steroids and Fat-Soluble Vitamins).** A. GANGL. With 1 Figure

## CHAPTER 17

**Intestinal Absorption of the Fat-Soluble Vitamins:****Physiology and Pharmacology.** J. A. BARROWMAN. With 8 Figures**Subject Index**

# Intestinal Absorption of Xenobiotics

T. Z. CSÁKY

## A. Introduction


A xenobiotic is a substance which is foreign to the living organism, but exposure to it affects the functions of the body. The effect can be therapeutically beneficial, i.e., pharmacologic, or harmful, i.e., toxic. The difference between pharmacologic and toxic action is more quantitative than qualitative. Essentially all therapeutically effective agents (drugs) can exert toxic effects in high enough doses. Consequently, in this chapter the expression “pharmacologic” will be used for basic properties of all xenobiotics, be they pharmacologic or toxic. Similarly, the expression “drug” will refer to xenobiotics in general. Several monographs have been published on the subject of drug absorption (BINNS 1964; HOUSTON and WOOD 1980; LEVINE 1971; PRESCOTT and NIMMO 1979).

## B. Drug Absorption and Pharmacologic Response

According to modern pharmacologic concepts, the vast majority of drug actions are the consequence of an interaction between the drug and a specific bodily receptor. The microcosmos in the immediate vicinity of the receptor is called the biophase. Usually the quantitative action of given drug depends on its concentration in the biophase. This, in turn, is determined by pharmacokinetics, viz., the absorption, distribution, and elimination of the drug in the body. Thus, the absorption process ultimately influences markedly the quantitative action of all xenobiotics.

Most drugs act reversibly, i.e., at equilibrium the rates of formation and dissociation of the drug-receptor complex are equal. Moreover, these rates are so high that they parallel the changes of the concentration of the drug in the biophase and, in turn, in the tissue water. The latter is in rapid equilibrium with the concentration of the unbound drug in the plasma. Consequently, the quantitative action of many drugs is directly related to their concentration in the plasma (BRODIE and MITCHELL 1973).

In humans, the gastrointestinal absorption of a given drug or drug product is usually expressed by the term “bioavailability” which is a measure of the rate and extent to which a drug is transferred from the gastrointestinal tract to the systemic circulation. Bioavailability is quantitated by the determination of the concentration of the drug in the blood plasma at given intervals following administration. Figure 1 indicates the information which can be obtained from the data. The following parameters are usually taken into consideration:




**Fig. 1.** Relationship between the effectiveness of the drug and its concentration in the blood plasma following oral administration. The AUC is shaded

1. The peak height to plasma or serum concentration.
2. The rate of absorption, i.e., the time between the administration and the achievement of the peak height concentration.
3. Total amount absorbed. This is measured from the area under the plasma or serum concentration–time curve and is expressed as AUC (area under curve).
4. Additional information can be obtained concerning the time needed for the onset, the duration, and the intensity of action.

Figure 2 illustrates how the variation of these parameters affects the quantitative action of the drug. Figure 2a depicts three hypothetical cases for the same drug in which the rate of absorption varied while the total amount absorbed (AUC) was unchanged. Figure 2b depicts three cases in which the rate was the same, but the fraction of the amount absorbed varied. From the analysis of these cases it is clear that the drug absorption is of particular concern in cases of drugs, such as analgesics, spasmolytics, or antiasthmatics, which are administered in a single dose for the purpose of reaching rapidly a definite plasma concentration level. Within this category, particularly if the drug has a narrow margin of safety, monitoring the plasma level is advisable. On the other hand, in case of drugs which are given in multiple doses to achieve and maintain a relatively constant plasma level, the rate of absorption is less a determining factor, but the total amount absorbed (AUC) may be significant.

### C. The Side of Drug Absorption

As will be seen, passive diffusion appears to be the most common process in the intestinal absorption of xenobiotics. In this process the rate is determined by the



**Fig. 2 a, b.** Influence of the variation in the rate of absorption (a) and in the fraction of the amount absorbed (b) upon the pharmacologic effectiveness. **a** Three hypothetical cases for the same drug in which the rate of absorption varied while the total amount absorbed (AUC) was unchanged. *A*, Drug level did not reach therapeutic effectiveness; *B*, therapeutic level was achieved; *C*, toxic level was obtained. **b** Three cases in which the rate was the same, but the fraction of the amount absorbed varied. *A*, Therapeutic level not reached; *B*, therapeutic level reached; *C*, toxic level obtained. *Broken lines*, the minimum blood level at which therapeutic or toxic effects, respectively, are achieved

area of the absorptive surface and the concentration difference between the lumen and the bloodstream. In the gastrointestinal tract the small intestine represents the largest absorptive surface, about 200 m<sup>2</sup> in an adult human (WILSON 1962), and is endowed with an abundant blood supply. Because of its much larger surface and better blood supply, the small intestine plays a significantly greater role than the stomach in the absorption of xenobiotics. This is true even with drugs which are fat soluble, such as ethanol (MAGNUSSEN 1968), or with weak acids, e.g., aspirin (SIURULA et al. 1969), which in the acid stomach are nonionized, thus becoming lipid soluble. Drugs and other xenobiotics can be absorbed also from the large intestine which represents a smaller area with less abundant blood supply. In living subjects after oral administration the drug absorption from the small intestine is sufficiently vigorous so that little reaches the large intestine.

Lipid-soluble drugs are readily absorbed from the rectum. The principal difference between intestinal and rectal absorption is that the veins from the intestine empty into the portal circulation, while the blood from the rectum is carried to a large extent through the hemorrhoidal veins into the vena cava, thus bypassing the liver. However, in humans this is not so clear-cut: a venous plexus collects the blood from the mucosa of the rectum. From this the upper hemorrhoidal veins carry the blood into the portal system, while the lower hemorrhoidal veins empty it via the iliac veins into the vena cava. Thus, in humans part of the rectally absorbed drug may end up in the portal system and part will be transported directly into the inferior vena cava. The situation is further complicated by individual variations which render the prediction of the circulatory fate of the rectally administered drug rather uncertain (DE BOER and BREIMER 1979).

#### D. The Intestinal Barrier and its Permeability

One can consider the intestine as a complex biologic membrane: it is composed essentially of the mucosal epithelial cells, the tight junction and intercellular